Zelgen

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (Stock Code: 688266), established in 2009, is located in the National High-tech Zone of Kunshan, Jiangsu Province. It has five subsidiaries: U.S.-based Gensun Biopharma, Shanghai Zelgen Pharmaceutical Technology Co., Ltd., Suzhou Zelgen Biotechnology Co., Ltd., Zelgen Pharmaceuticals (Zhejiang) Co., Ltd., and Zelgen Holdings Limited. Zelgen focuses on the independent research, production, and commercialization of innovative drugs. The company aims to become a leading enterprise in the research and production of new drugs for oncology, hemorrhagic and hematological diseases, immune-inflammatory diseases, and hepatobiliary diseases in China. Its market strategy is global-oriented while focusing on China, developing and producing innovative drugs with independent intellectual property rights that are safe, effective, and affordable for patients, to meet the enormous pharmaceutical market demands both domestically and internationally. A rich pipeline of new drugs ensures the company's success. With extensive experience and expertise in new drug development, Zelgen has successfully built two distinctive core technology platforms: a small molecule drug R&D and industrialization platform, and a complex recombinant protein and antibody drug R&D and industrialization platform. Leveraging these two platforms, the company has developed a robust product pipeline of small molecule drugs and recombinant protein drugs, covering various cancers such as liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal cancer, myeloproliferative neoplasms, as well as therapeutic areas like hemorrhage, immune-inflammatory diseases, and hepatobiliary diseases.